Pre-made Ganitumab benchmark antibody ( Whole mAb, anti-IGF1R therapeutic antibody, Anti-IGFR/CD221/IGFIR/JTK13 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Ganitumab biosimilar, Whole mAb, Anti-IGF1R Antibody: Anti-IGFR/CD221/IGFIR/JTK13 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ganitumab a human monoclonal antibody against type 1 insulin-like growth factor receptor (IGF1R), designed for the treatment of cancers.
| Products Name (INN Index) | Pre-Made Ganitumab biosimilar, Whole mAb, Anti-IGF1R Antibody: Anti-IGFR/CD221/IGFIR/JTK13 therapeutic antibody |
|---|---|
| INN Name | Ganitumab |
| Target | IGF1R |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2010 |
| Year Recommended | 2011 |
| Companies | Amgen,Millennium,NantWorks,National Cancer Institute (USA),Novartis,Takeda,Takeda Oncology,UCLAs Jonsson Comprehensive Cancer Center |
| Conditions Approved | NA |
| Conditions Active | Ewing's sarcoma,Solid tumours,Rhabdomyosarcoma |
| Conditions Discontinued | Breast cancer,Colorectal cancer,Sarcoma,Small cell lung cancer,Non-small cell lung cancer,Pancreatic cancer,Prostate cancer |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | IGF1R |
| Package |
